|
(2008, 1300 words)
The paper examines the factors that affected the share prices of AstraZeneca and GlaxoSmithKline, placing particular focus on the Company announcement published in the London Stock Exchange. A short overview of the company ratios is given suggesting recommendations for investors.
(2007, 1400 words)
AstraZeneca Plc, a leading global pharmaceutical company, specialises in cardiovascular, gastrointestinal, infection, neuroscience, oncological and respiratory therapies. AstraZeneca's key products such as Nexium, Seroquel, Crestor, Arimidex, and Symbicort achieved good sales growth for the third quarter of 2006 in a highly competitive drug making sector. Yet the Company's global sales ranks fourth behind GlaxoSmithKline, Sanofi-Aventis and Novartis. Issues raised in this report denotes a critical dimension that may weaken or strengthen AstraZeneca's position in taking advantage of the opportunities occurring and key developments expected in the pharmaceutical industry in five years from now.
(2006, 2500 words)
The report provides a strategic analysis for one of the world’s well known pharmaceutical companies, AstraZeneca. The report has been divided into three basic parts: external environment analysis, internal environment analysis and options development. The external environment analysis has been provided with the help of PEST, Industry Lifecycle and Porter’s Five Forces analyses. The internal environment analysis has been provided by using value chain and hierarchy of resources of the company. The implications of these have been used to develop strategic options with the scenario planning process. The evaluations of these strategic options have also been provided by suitability, acceptability and feasibility indicators.
(2006, 4500 words)
The paper reports on AstraZeneca (AZN), a UK based pharmaceutical company, describing the company’s structure, reviewing their recent deals, and conducting analysis of the pharmaceutical industry, the trends in the industry benchmarks ratios, and the analysis of AstraZeneca’s income statements, balance sheets, cash flow statements, etc. The company’s benchmark ratios are compared to those of their main rivals. Conclusions are made about whether AstraZeneca is a profitable investment.
(2005, 2500 words)
This paper examines the competitive position of AstraZeneca PLC, identifying the key environmental influences and the main drivers for change through the use of PESTEL and SWOT analyses; and the key competitive forces through the use of Porters 5 Forces. This paper then provides recommendations of the strategic options available to AstraZeneca.
(2004, 1000 words)
The paper investigates the features of organisational behaviour reporting on the pharmaceutical industry and using the performance of the AstraZeneca Company as an example. The structure of the industry is outlined. Passive and active modes of organisational behaviour at the company are discussed.
(2004, 1000 words)
The paper examines the performance of Astrazeneca (AZN), an Anglo/Swedish pharmaceutical company, on the London Stock Exchange (LSE). A point by point analysis of its major share movements over a year's period is given. Conclusions are made about the variables that make the sector more volatile than the average.
(2004, 15000 words)
This dissertation looks at the 1999, cross-border merger, of Sweden's Astra AB and the UK's Zeneca PLC to form AstraZeneca PLC. The paper asks the question ?What motivated two successful companies, Astra AB and Zeneca PLC, to merge and was the merger successful in terms of shareholder wealth?. It examines the merger by assessing each organisation prior to merger, the strategic process and cultural impact of merging, the financial and cultural organisation post merger, concluding with an assessment of success. The paper is thoroughly researched, presents an in-depth bibliography and uses a good range of analytical tools and models
|
